Long-term follow-up with updated time to disease progression (TTP) and duration of response (DR) data are presented from a multicenter, phase II trial of rituximab/cyclophosphamide, doxorubicin, ...
This was an open-label, single-arm, single-center phase II study enrolling 40 patients. During the first week of the study, patients received two infusions of rituximab 375 mg/m 2 administered 4 days ...
Primary thyroid lymphoma (PTL) is an uncommon thyroid malignancy, representing approximately 1–5% of thyroid cancers and 2.5–7% of extranodal lymphomas. Predominantly of B‐cell origin, PTL most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback